The health technology assessment agency has recommended in final draft guidance that the drug be used in combination with AZ’s endocrine therapy Faslodex (fulvestrant) to treat adults on the NHS in England and Wales with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with at least one PIK3CA, AKT1 or PTEN gene alteration.
Patients eligible for the therapy will also have experienced disease recurrence or progression after a CDK4/6 inhibitor plus an aromatase inhibitor…
